MythiliKoneruMDPh.D.

Chief Medical Officer

Dr. Koneru is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2008 - 2011
Rutgers Robert Wood Johnson Medical SchoolClass of 2008

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Start of enrollment: 2020 Oct 14
Active, not recruiting
Phase 2
Roles: Study Director, Contact
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Start of enrollment: 2023 Jan 02
Recruiting
Phase 1
Roles: Contact

PubMed

35 citations
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
Mark H. O'Hara, Wells A. Messersmith, Hedy L. Kindler, Wei Zhang, Celine Pitou
Journal of Pancreatic Cancer. 2020-03-12
29 citations
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Prajwal Boddu, Gautam Borthakur, Mythili Koneru, Xuelin Huang, Kiran Naqvi
Frontiers in Oncology. 2018-09-24
271 citations
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.
Oladapo Yeku, Terence J. Purdon, Mythili Koneru, David R. Spriggs, Renier J. Brentjens
Scientific Reports. 2017-09-05

MRKR (Marker Therapeutics, Inc): Something with Huge Risk:RewardJuly 19th, 2021
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell TransplantMarch 3rd, 2021
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. As Senior Vice President, Clinical DevelopmentFebruary 7th, 2019
Join now to see all